Form 4: Pfizer SVP & Controller Settles Stock Appreciation Rights

Pfizer's SVP & Controller, Jennifer B. Damico, settled 17,558 stock appreciation rights, resulting in a net beneficial ownership of 12,696 common shares.

Summary

• Jennifer B. Damico, SVP & Controller of Pfizer Inc., settled 17,558 Stock Appreciation Rights (SARs).
• This transaction involved the acquisition of 17,558 shares of common stock at an exercise price of $33.82 per share.
• 361 shares were disposed of at $27.09 per share to satisfy tax obligations related to the SAR earn-out.
• An additional 16,687 shares were disposed of at $26.92 per share to cover the payment of the exercise price in connection with the SAR earn-out.
• Following these transactions, Damico's direct beneficial ownership of Pfizer common stock is 12,696 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction with no direct operational or financial impact on Pfizer Inc.

Positives

• Executive Jennifer B. Damico exercised 17,558 Stock Appreciation Rights, a standard component of executive compensation.

Negatives

• No direct negative implications for the company's operations or financial health are indicated by this routine executive compensation event.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that the settlement of Stock Appreciation Rights is a common form of executive compensation in the pharmaceutical industry, aligning executive incentives with shareholder value creation over time.

Comparison to Industry Standards

• This type of executive compensation event, involving the exercise and net settlement of equity awards, is standard practice across large-cap pharmaceutical companies such as Johnson & Johnson, Merck, and Bristol Myers Squibb, reflecting typical long-term incentive structures.

Stakeholder Impact

• Shareholders: No direct impact on company operations or strategy; reflects standard executive compensation practices.

Key Dates

Recommendation

This Form 4 details a standard executive compensation event involving the settlement of Stock Appreciation Rights. It does not provide new information regarding Pfizer's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Stock Appreciation Rights, Executive Compensation, Jennifer B. Damico